CENTOGENE - transforming genetic data into medical decisions. We are one of the worldwide leaders in the field of early genetic diagnostics for rare hereditary diseases. A data repository of genetic data from over 115 countries gives us a unique access to epidemiological, clinical and genetic information on hereditary disorders, including oncogenetic indications.
We focus exclusively on providing the highest quality, patient-centred service, verified by multiple international accreditations (ISO, CAP, CLIA), regular pharmaceutical audits and our outstanding short turn-around times for analysis. We believe our medical expertise is based on cutting-edge technologies including whole exome/genome sequencing, innovative biomarkers and continued R&D. Our mutation database (CentoMD®) is the world’s largest for rare genetic diseases and is pivotal to our high-quality diagnostic reporting and comprehensive medical interpretation. CENTOGENE is a key partner for many high-profile pharmaceutical companies who are active in the orphan drug development.
Location: United Arab Emirates, Dubai
Employees: 501-1000
Phone: +49 381 80113416
Total raised: $28.02M
Founded date: 2006
Investors 1
| Date | Name | Website |
| - | TVM Capita... | tvm-lifesc... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.06.2017 | Series A | $28.02M | - |
Mentions in press and media 15
| Date | Title | Description |
| 15.05.2024 | CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position | - |
| 02.07.2023 | Lifera and CENTOGENE, Enter Strategic Collaboration - Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing | Joint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly owned by the Public Investment Fund (PIF) based in Riyadh. JV focuses on providing state-of-the-art mul... |
| 19.04.2023 | Startup Showcase: Centogene – Revolutionizing the Diagnosis of Rare Inherited Diseases | Centogene is a leading genetic biotech company that provides innovative methods and technology for human genetics analysis. The company is a global leader in genetic diagnostic analyses of rare inherited diseases, transforming global geneti... |
| 06.10.2022 | CENTOGENE to Participate in Upcoming Partnering Conferences in October | CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, today announced its par... |
| 04.01.2022 | CENTOGENE's CentoCloud® Set to Revolutionize Rare Disease Diagnostics With Decentralized SaaS Platform for Laboratories Around the World | The CentoCloud solution is a cloud-based Software as a Service (SaaS) platform that enables laboratories around the world to analyze, interpret, and report genomic variants, and will be able to utilize the power of proprietary reagent kits ... |
| 04.01.2022 | Centogene N : CentoCloud® Set to Revolutionize Rare Disease Diagnostics With Decentralized SaaS Platform for Laboratories Around the World - Form 6-K | CENTOGENE's CentoCloud® Set to Revolutionize Rare Disease Diagnostics With Decentralized SaaS Platform for Laboratories Around the World · The CentoCloud solution is a cloud-based Software as a Service (SaaS) platform that enables laborator... |
| 24.11.2021 | Centogene N : Reports Third Quarter 2021 Financial Results - Form 6-K | CENTOGENE Reports Third Quarter 2021 Financial Results Second Consecutive Quarter of Core Business Growth, Phasing Out COVID-19 Testing and Restructuring Organization for Core Rare Disease Business CAMBRIDGE, Mass. and ROSTOCK, Germany... |
| 04.11.2021 | CENTOGENE Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases - Form 6-K | CENTOGENE Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases Providing Global Clinical Trial Support for Thalassemia and Sickle Cell Disease Will Deepen Understanding of Disease Characterization in the Search... |
| 07.06.2021 | CENTOGENE N.V. Centogene N : Announces Virtual Investor Event (Form 6-K) | CENTOGENE Announces Virtual Investor Event New leadership team to present vision, strategy, and execution roadmap CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 7, 2020 (GLOBE NEWSWIRE) - Centogene N.V. (Nasdaq: CNTG), a commercial-... |
| 03.09.2020 | CENTOGENE : Publishes Huge Dataset that Supports Genome Sequencing as a First-Line Diagnostic Test | DGAP-News: Centogene NV / Key word(s): Scientific publication CENTOGENE Publishes Huge Dataset that Supports Genome Sequencing as a First-Line Diagnostic Test 03.09.2020 / 12:30 The issuer is solely responsible for the content of this annou... |
Show more